Atrial fibrillation is strongly associated with an increased risk of cognitive decline and dementia, which may be mitigated by appropriate use of anticoagulation and rhythm control strategies.
Does the management of atrial fibrillation with anticoagulation, rate control, or catheter ablation reduce the risk of dementia?
Effective management of atrial fibrillation, including anticoagulation and ablation, may reduce the associated risk of dementia, though prospective trials are needed to confirm observational findings.
AF is strongly associated with a spectrum of cranial injuries including stroke and dementia. Dementia risk is seen in patients with and without a prior stroke and includes idiopathic forms of dementia, such as Alzheimer's disease. The initiation, use and efficacy of anticoagulation have been shown in multiple observational trials to have an impact on dementia risk. Cerebral hypoperfusion during AF can result in cognitive decline and patients with cranial atherosclerosis may have unique susceptibility. Therapies to carefully control the ventricular rate and catheter ablation have been shown in observational trials to lower dementia risk. There is a need for further research in multiple areas and the observational trials will require prospective trials confirmation. Recent guidelines for AF have advocated the initiation of effective anticoagulation, the treatment of associated disease conditions that may influence the progression of AF and catheter ablation, with long-term management of risk factors to lower risk of dementia.
Bunch et al. (Tue,) conducted a review in Atrial Fibrillation and Dementia. Atrial fibrillation is strongly associated with an increased risk of cognitive decline and dementia, which may be mitigated by appropriate use of anticoagulation and rhythm control strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: